Emphasizing the Burden of proof: The American college of cardiology 2008 expert panel comments on the ENHANCE trial

Circulation: Cardiovascular Quality and Outcomes

Volumn 3, Issue 6, 2010, Pages 565-567

  Krumholz, Harlan M ^a,b,c  

^a Robert Wood Johnson Clinical Scholars Program   (United States)

^b YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c YALE NEW HAVEN HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ENCAINIDE; EZETIMIBE; EZETIMIBE PLUS SIMVASTATIN; FIBRIC ACID DERIVATIVE; FLECAINIDE; LOW DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NICOTINIC ACID; RESIN; SIMVASTATIN; TORCETRAPIB;

ARTERIAL WALL THICKNESS; ATHEROSCLEROSIS; CARDIOVASCULAR RISK; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DRUG COST; DRUG EFFICACY; HUMAN; HYPERCHOLESTEROLEMIA; MEDICAL DECISION MAKING; MONOTHERAPY; PRESCRIPTION; PRIORITY JOURNAL; REVIEW; RISK BENEFIT ANALYSIS; TREATMENT OUTCOME;

ANTICHOLESTEREMIC AGENTS; ATHEROSCLEROSIS; AZETIDINES; BIOLOGICAL MARKERS; CARDIOLOGY; CAROTID ARTERIES; CLINICAL TRIALS AS TOPIC; CLINICAL TRIALS DATA MONITORING COMMITTEES; EVIDENCE-BASED MEDICINE; EXPERT TESTIMONY; HUMANS; HYPERCHOLESTEROLEMIA; LIPOPROTEINS, LDL; SIMVASTATIN;

EID: 78650191019     PISSN: 19417713     EISSN: 19417705     Source Type: Journal    
DOI: 10.1161/CIRCOUTCOMES.110.959577     Document Type: Review

References (16)

1. Winslow R, Rubenstein S. Trial and error: delays in drug's test fuel wider data debate. Wall Street Journal. March 24, 2008.
2. Kastelein JJ, Akdim F, Stroes ES, Zwinderman AH, Bots ML, Stalenhoef AF, Visseren FL, Sijbrands EJ, Trip MD, Stein EA, Gaudet D, Duivenvoorden R, Veltri EP, Marais AD, de Groot E. Simvastatin with or without ezetimibe in familial hypercholesterolemia. N Engl J Med. 2008;358:1431-1443.
3. Smilde TJ, van Wissen S, Awollersheim H, Trip MD, Kastelein JJP, Stalenhoef AFH. Effect of aggressive versus conventional lipid lowering on atherosclerosis progression in familial hypercholesterolemia (ASAP): a prospective, randomized, double-blind trial. Lancet. 2001;357:577-581.
4. Wiegman A, Hutten BA, de Groot E, Rodenburg J, Bakker HD, Büller HR, Sijbrands EJ, Kastelein JJ. Efficacy and safety of statin therapy in children with familial hypercholesterolemia: a randomized controlled trial. JAMA. 2004;292:331-337.
5. Brown BG, Taylor AJ. Does ENHANCE diminish confidence in lowering LDL or in ezetimibe? N Engl J Med. 2008;358:1504-1507.
6. Duckworth W, Abraira C, Moritz T, Reda D, Emanuele N, Reaven PD, Zieve FJ, Marks J, Davis SN, Hayward R, Warren SR, Goldman S, McCarren M, Vitek ME, Henderson WG, Huang GD. Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med. 2009;360:129-139.
7. Gerstein HC, Miller ME, Byington RP, Goff DC Jr, Bigger JT, Buse JB, Cushman WC, Genuth S, Ismail-Beigi F, Grimm RH Jr, Probstfield JL, Simons-Morton DG, Friedewald WT. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med. 2008;358:2545-2559.
8. Patel A, MacMahon S, Chalmers J, Neal B, Billot L, Woodward M, Marre M, Cooper M, Glasziou P, Grobbee D, Hamet P, Harrap S, Heller S, Liu L, Mancia G, Mogensen CE, Pan C, Poulter N, Rodgers A, Williams B, Bompoint S, de Galan BE, Joshi R, Travert F. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med. 2008;358:2560-2572.
9. Ginsberg HN, Elam MB, Lovato LC, Crouse JR III, Leiter LA, Linz P, Friedewald WT, Buse JB, Gerstein HC, Probstfield J, Grimm RH, Ismail-Beigi F, Bigger JT, Goff DC Jr, Cushman WC, Simons-Morton DG, Byington RP. ACCORD Study Group. Effects of combination lipid therapy in type 2 diabetes mellitus. N Engl J Med. 2010;362:1563-1574.
10. Cushman WC, Evans GW, Byington RP, Goff DC Jr, Grimm RH Jr, Cutler JA, Simons-Morton DG, Basile JN, Corson MA, Probstfield JL, Katz L, Peterson KA, Friedewald WT, Buse JB, Bigger JT, Gerstein HC, Ismail-Beigi F. Effects of intensive blood-pressure control in type 2 diabetes mellitus. N Engl J Med. 2010;362:1575-1585.
11. Pfeffer MA, Burdmann EA, Chen CY, Cooper ME, de Zeeuw D, Eckardt KU, Feyzi JM, Ivanovich P, Kewalramani R, Levey AS, Lewis EF, McGill JB, McMurray JJ, Parfrey P, Parving HH, Remuzzi G, Singh AK, Solomon SD, Toto R. A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease. N Engl J Med. 2009;361:2019-2032.
12. Institute of Medicine of the National Academies (Committee on Qualification of Biomarkers and Surrogate Endpoints in Chronic Disease). Evaluation of biomarkers and surrogate endpoints in chronic disease. Washington DC: Institute of Medicine. May 12, 2010.
13. Krumholz HM. Circulation: Cardiovascular Quality and Outcomes: Scholarship to improve health and health care for patients and populations. Circ Cardiovasc Qual Outcomes. 2008;1:1-3.
14. Krumholz HM. Outcomes research: myths and realities. Circ Cardiovasc Qual Outcomes. 2009;2:1-3.
15. Krumholz HM. Medicine in the era of outcomes measurement. Circ Cardiovasc Qual Outcomes. 2009;2:141-143.
16. Krumholz HM. Focusing on outcomes in Circulation: Cardiovascular Quality and Outcomes. Circ Cardiovasc Qual Outcomes. 2010;3:332-4.